High plasma levels of soluble Fas in HIV type 1-infected subjects are not normalized during highly active antiretroviral therapy

AIDS Research and Human Retroviruses

Volumn 16, Issue 14, 2000, Pages 1379-1384

  De Milito, A ^a,b   Hejdeman, B ^c   Albert, J ^d   Aleman, S ^d   Sonnerborg, A ^d   Zazzi, M ^b,e   Chiodi, F ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF SIENA   (Italy)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e General Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; FAS ANTIGEN; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIREMIA; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIGENS, CD95; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MATCHED-PAIR ANALYSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TIME FACTORS; VIREMIA; VIRUS REPLICATION;

EID: 0034692559     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220050140928     Document Type: Article

References (26)

1. Treatment of human immunodeficiency vires infection with saquinavir, zidovudine and zalcitabine
2. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
3. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy
4. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
5. Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment
6. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)
7. Role of lymphoid organs in the pathogenesis of human immunodeficiency vires (HIV) infection
8. T helper cell activation and human retroviral pathogenesis
9. Dynamic correlation of apoptosis and immune activation during treatment of HIV infection
10. Expression of CD38 on CD8 T cells predicts maintenance of high viraemia in HAART-treated HIV-1-infected children. Highly active antiretroviral therapy
11. Phenotypic analysis of CD8+ T lymphocytes in a cohort of HIV type 1-infected patients treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA
12. CD8+ anti-human immunodeficiency virus suppressor activity (CASA) in response to antiretroviral therapy: Loss of CASA is associated with loss of viremia
13. Restoration of normal interleukin-2 production by CD4+ T cells of human immunodeficiency virus-infected patients after 9 months of highly active antiretroviral therapy
14. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults
15. The Fas death receptor
16. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing
17. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule
18. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals
19. Programmed cell death in peripheral lymphocytes from HIV-infected persons: The increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression
20. Elevated serum levels of soluble Fas/APO-1 in human immunodeficiency virus-infected individuals
21. Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from human immunodeficiency virus-infected persons
22. Apoptosis and the CD95 system in HIV disease: Impact of highly active antiretroviral therapy (HAART)
23. In vivo analysis of Fas/FasL interactions in HIV-infected patients
24. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HVI-1 disease
25. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: Persistent TNF activation is associated with virologic and immunologic treatment failure
26. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo